91944-48-8

Upstream product

• 34331-40-3 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl methanesulfonate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 198275-89-7 4-(4-bromophenyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 14697-49-5 4-(2,3-epoxy)propyloxybenzaldehyde 
• 67-64-1 acetone 

Downstream Products

• 878498-93-2 {4-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]benzylidene}malononitrile 
• 91944-34-2 2-[[p-[3-[2-(3,4-Dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]phenyl]]imidazole 
• 85613-31-6 2-[p-(3-Cyclopropylamino-2-hydroxypropoxy)phenyl]-imidazole 
• 85613-29-2 Methanesulfonic acid 2-hydroxy-3-[4-(1H-imidazol-2-yl)-phenoxy]-propyl ester 
• 85613-28-1 3-[p-(2-imidazolyl)phenoxy]-1,2-propanediol 
• 85613-45-2 3--1,2-epoxypropane 
• 85613-27-0 3--1,2-propanediol acetonide 

Relevant academic research and scientific papers

Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases

The present invention relates to the use of A1 and/or dual A1/A2b agonists of the formulae (IA) and (IB) for preparing a medicament for treating dyslipidemia, metabolic syndrome and diabetes and dyslipidemia, metabolic syndrome and diabetes in association with hypertension and cardiovascular disorders.

Substituted Phenylaminothiazoles and Use Thereof

The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.

Ring-opening reactions of epoxides catalyzed by molybdenum(VI) dichloride dioxide

Transformation of epoxides to β-alkoxy alcohols, acetonides, and α-alkoxy ketones is achieved by using molybdenum(VI) dichloride dioxide (MoO2Cl2) as a catalyst. Alcohol, aldehyde, oxime, tosyl, and tert-butyldimethylsilyl functional groups are tolerated during the methanolysis and acetonidation of the functionalized epoxides. No polymerization product is observed with any of the epoxides. Direct conversion of epoxides devoid of sensitive functional groups into the corresponding α-methoxy ketone is achieved in a single step by using the MoO2Cl 2/Oxone system. Georg Thieme Verlag Stuttgart.

INSECTICIDAL BIS(SUBSTITUTED PHENYL)-1-{[4-(SATURATED HETEROCYCLYL-SUBSTITUTED)PHENYLMETHYL]-(4-PIPERIDYL)}METHANE DERIVATIVES

It has now been found that certain novel bis(substituted phenyl)-1- {[4-(saturated heterocyclyl-substituted)phenylmethyl](4-piperidyl)}methane derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I); where R through R15,m, n, s, A, B, D and W are defined herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula (I), and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.

SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF

The invention relates to novel phenylaminothiazole derivatives, methods for the production thereof, the use thereof for treating and/or preventing diseases, and the use thereof for producing medicaments used for treating and/or preventing diseases, preferably hypertension and other cardiovascular diseases.

β1-Selective adrenoceptor antagonists: Examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class

A series of 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazoles is described. The compounds were investigated in vitro for β-adrenoceptor antagonism, and several examples were found to be selective for the β1-adrenoceptor. The structure-activity relationship exhibited by this series of compounds is discussed. (S)-2-[p-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropoxy]phenyl] -4-(2-thienyl)imidazole [(S)-13] was over 100 times more selective than atenolol for the β1-adrenergic receptor and has been selected for in-depth studies.